おすすめの製品
由来生物
mouse
品質水準
結合体
unconjugated
抗体製品の状態
purified immunoglobulin
抗体製品タイプ
primary antibodies
クローン
26503, monoclonal
フォーム
lyophilized powder
交差性
primate, human
テクニック
capture ELISA: 2-8 μg/mL
neutralization: suitable
western blot: 1-2 μg/mL
アイソタイプ
IgG2b
UniProtアクセッション番号
保管温度
−20°C
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... VEGFA(7422) , VEGFB(7423) , VEGFC(7424)
詳細
組み換えヒトVEGF165の生物活性を中和する抗体です。VEGF121も認識します。
免疫原
Sf21で発現させたリコンビナントヒトVEGF(165アミノ酸アイソフォ-ム)の精製物
アプリケーション
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Monoclonal Anti-Vascular Endothelial Growth Factor antibody produced in mouse was used to block the interaction between VEGF and kinase domain receptor in Calf Pulmonary Aortic Endothelial (CPAE) cells.
生物化学的／生理学的作用
The vascular endothelial growth factor family consists of five members, VEGF-A to VEGF-E. They play important roles in important role in embryonic vasculogenesis, angiogenesis and homeostasis. The interaction between VEGFs and their respective receptors results in the activation of MAPK, PI3K, PKC, FAK and Src kinase pathways.
物理的形状
凍結乾燥品(PBS溶液, 5%トレハロ-ス含有, 0.2μmフィルタ-濾過済み)。
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
個人用保護具 (PPE)
Eyeshields, Gloves, type N95 (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
V4758-BULK:
V4758-.5MG:
V4758-.5MG-PW:
V4758-VAR:
Esther Grueso et al.
Journal of virology, 93(19) (2019-07-19)
As many tumor cells synthetize vascular endothelial growth factors (VEGF) that promote neo-vascularization and metastasis, frontline cancer therapies often administer anti-VEGF (α-VEGF) antibodies. To target the oncolytic parvovirus minute virus of mice (MVM) to the tumor vasculature, we studied the
Tali Lange et al.
The Journal of biological chemistry, 278(19), 17164-17169 (2003-02-25)
The splice forms of vascular endothelial growth factor (VEGF) differ in biological properties such as the receptor types that they recognize and their interaction with heparan sulfate proteoglycans. We have identified a new VEGF mRNA splice form encoding a VEGF
Giuseppa Gennaro et al.
Circulation, 107(2), 230-233 (2003-01-23)
The mechanisms responsible for the association between advanced age and atherosclerotic diseases are not clear. Because atherosclerosis develops in response to local endothelial injuries, we investigated the effect of aging on vascular healing and reendothelialization. Endothelium denudation was performed by
Dong-Kwon Lim et al.
Biomaterials, 77, 130-138 (2015-11-21)
Vascular endothelial growth factor 165 (VEGF165) is an important extracellular protein involved in pathological angiogenesis in diseases such as cancer, wet age-related macular degeneration (wet-AMD) and retinitis pigmentosa. VEGF165 exists in two different isoforms: the angiogenic VEGF165a, and the anti-angiogenic
R Binétruy-Tournaire et al.
The EMBO journal, 19(7), 1525-1533 (2000-04-04)
Vascular endothelial growth factor (VEGF) binding to the kinase domain receptor (KDR/FLK1 or VEGFR-2) mediates vascularization and tumor-induced angiogenesis. Since there is evidence that KDR plays an important role in tumor angiogenesis, we sought to identify peptides able to block
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）